Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
News|Articles|October 11, 2019
Evaluating the Changing CDMO Landscape
Author(s)Pharmaceutical Technology Editors
During the first day of CPhI Worldwide in Frankfurt, Germany, a panel of experts will be discussing the evolution of CDMOs in the shifting therapeutic landscape.
Advertisement
During the first day of CPhI Worldwide in Frankfurt, Germany (Tuesday, Nov. 5, 2019), a panel of experts will be discussing the evolution of contract development and manufacturing organizations (CDMOs) in the shifting therapeutic landscape.
In the Pharma Insight Briefings session, which is set to take place at 10:30 am until 11:40 am in hall 12.0 stand 120D40, some of the key questions facing CDMOs will be broached. Topics for consideration will include whether the ‘one-stop-shop’ concept is no longer applicable, the impact of M&A activities as well as consolidation in the industry, and flexible manufacturing approaches.
The panel of experts will be Peter Bigelow (xCell Strategic Consulting), Daniel Bourgin (Dr. Reddy’s Custom Pharma Services), Bikash Chatterjee (Pharmatech Associates), Anil Kane (Patheon, part of Thermo Fisher Scientific), Jim Miller (founder and former president, PharmSource), Peter Shapiro (PharmSource), Jeremie Trochu (Catalent), and Ganesh Vaidyanathan (Dr. Reddy’s Custom Pharma Services).
Exploring Trends in Contract ManufacturingTuesday Nov. 5, 2019 10:30–11:40 ICSE Theatre (120D40)
Advertisement
Related to this article
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Advertisement
Advertisement